[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wonju Severance Christian Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":290},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,73,105,130,157,184,208,236,266],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100535352","hativ-electrocardiogram-monitoring-on-patients-with-suspected-arrhythmia-100535352",false,"NCT06250712","Hativ® ELectrocardiogram Monitoring on Patients With Suspected Arrhythmia","HELP-A","Inclusion Criteria:\n\n* Patients who have arrhythmia symptoms but are not diagnosed on a 12-lead electrocardiogram and require additional tests.\n* Patients who can use a smartphone\n\nExclusion Criteria:\n\n* Patients who have cardiac implantable electronic devices(CIEDs)\n* Patients who can't use handheld ECG","ALL","19 Years",{"count":19,"type":20},588,"ESTIMATED","INTERVENTIONAL",[23],"NA","HELP-A study is a single-center, randomized, controlled trial. A total of 588 patients enrolled during the 2 years of enrollment period and followed for 1 month of follow-up period. This study aims to compare diagnostic yield between continuous ECG Patch and intermittent handheld ECG in patients with arrhythmia symptoms.",[26],"Arrhythmia",[28,29,26],"Palpitation","Dizziness","RECRUITING","2025-09-22",{"date":33,"type":34},"2025-09-26","ACTUAL",{"date":36,"type":34},"2024-02-22",{"date":38,"type":20},"2025-12-31",{"name":40,"class":41},"Wonju Severance Christian Hospital","OTHER",3,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100604181","long-term-follow-up-of-bio-signals-and-quality-of-recovery-following-implementation-of-eras-100604181","NCT07146178","Long-term Follow-up of Bio-signals and Quality of Recovery Following Implementation of ERAS","Long-term Follow-up of Bio-signals and Quality of Recovery Following Implementation of Enhanced Recovery After Surgery(ERAS) Program","Inclusion Criteria:\n\n* Age between 20 and 70 years\n* Scheduled to undergo gynecologic laparoscopic surgery under general anesthesia\n* Use of an Android smartphone\n\nExclusion Criteria:\n\n* American Society of Anesthesiologists(ASA) physical status classification IV or higher\n* Body Mass Index (BMI) 35 or higher\n* Presence of diabetic autonomic neuropathy\n* History of esophageal hiatal hernia or delayed stomach discharge\n* Known allergy to local anesthesia\n* Participantion in other trials that may affect study outcomes\n* Inability to complete questionnaires (e.g., due to cognitive impairment)","FEMALE","20 Years","70 Years",{"count":54,"type":20},200,[23],"The goal of this clinical trial is to evaluate the effect of an Enhanced Recovery After Surgery(ERAS) protocol in patients undergoing gynecologic laparoscopic surgery under general anesthesia. The main question it aims to answer is: Does the ERAS protocol improve the quality of recovery compared to standard treatments?\n\nResearchers will compare ERAS protocol with standard treatment to see if ERAS protocol improves the quality of recovery after surgery.\n\nParticipants will:\n\n* Receive ERAS protocol during the hospitalization\n* Undergo bio-signal monitoring for one month using Hi-Cardi Plus device and Galaxy Watch 7\n* Visit the hospital at one week and one month after discharge\n* Complete questionnaires(QOR-15K, WHO-DAS 2.0, EQ-5D-3L) at 24 hours after surgery, at discharge, one week after discharge, and one month after discharge",[58,59],"Gynecologic Surgery","General Anesthesia",[61,62],"Enhanced recovery after surgery","bio-signal monitoring","NOT_YET_RECRUITING","2025-08-21",{"date":66,"type":34},"2025-08-28",{"date":68,"type":20},"2025-09-01",{"date":70,"type":20},"2026-10-01",{"name":40,"class":41},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":80,"enrollmentInfo":81,"targetDuration":83,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":91,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":72},"100475748","sudden-sensorineural-hearing-loss-in-wonju-severance-christian-hospital-100475748","NCT05474963","Sudden Sensorineural Hearing Loss in Wonju Severance Christian Hospital","Prospective Cohort Study of Sudden Sensorineural Hearing Loss in Wonju Severance Christian Hospital","Inclusion Criteria:\n\n* Adult patients over 20 years of age\n* A patient who visited Wonju Severance Christian Hospital, Department of Otolaryngology and was diagnosed with sudden hearing loss as it was confirmed that hearing loss of 30dBHL or more occurred within 3 days at three consecutive frequencies in a pure tone audiometry test.\n* Those who have fully explained the purpose and content of the study and voluntarily agreed to the written consent\n\nExclusion Criteria:\n\n* If the patients do not want to or do not fill out the consent form\n* If treatment is started for sudden hearing loss, but the possibility of other inner ear diseases including Meniere's disease is suspected due to repeated hearing loss, repeated recovery, dizziness, tinnitus, etc.\n* Other cases where it is judged difficult to carry out the clinical trial due to the judgment of the person in charge of the above clinical trial","100 Years",{"count":82,"type":20},1000,"6 Months","OBSERVATIONAL","This study is to build a cohort of sudden sensorineural hearing loss (SSNHL) patients. When the patient visited the Department of otolaryngology clinic for hearing loss, we can diagnose the SSNHL following the result of pure tone audiometry and the history of the patient. The cohort is a system that tracks the hearing recovery status, timing, and degree of recovery of patients who received cocktail therapy with or without high-dose steroids, vasodilators, antiviral agents, and intratympanic steroid injections, satellite ganglion block, and hyperbaric oxygen therapy.",[87,88,89,90],"SSNHL(Sudden Sensory Neural Hearing Loss)","Sudden Hearing Loss","Hearing Loss, Idiopathic Sudden Sensorineural","Hearing Loss, Sudden",[92,93,94,95,96],"Hearing Loss","Hearing Loss, sudden","SSNHL","Sudden sensorineural hearing loss","sudden sensory neural hearing loss","2025-03-23",{"date":99,"type":34},"2025-03-26",{"date":101,"type":34},"2021-07-14",{"date":103,"type":20},"2035-12-31",{"name":40,"class":41},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":72},"100579394","taekwondo-for-axial-spondyloarthritis-100579394","NCT06823726","Taekwondo for Axial Spondyloarthritis","Efficacy and Safety of a 12-Week Taekwondo Training Program in Patients With Ankylosing Spondylitis and Axial Spondyloarthritis: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Diagnosed with axial spondyloarthritis (axSpA) according to the ASAS classification criteria.\n2. Age: Between 19 and 59 years old.\n3. Stable medication or non-medication treatment:\n\n   * Patients whose medication regimen has remained stable for at least the past 3 months.\n   * Patients who have not taken medication for axSpA for at least the past 3 months.\n\nExclusion Criteria:\n\nParticipants will be excluded from the study if they meet any of the following conditions:\n\n1. History of orthopedic surgery or fractures within the past 12 months.\n2. History of cardiovascular diseases, including ischemic heart disease, cardiomyopathy, heart failure, or stroke.\n3. Advanced ankylosis in ankylosing spondylitis, as confirmed by radiographic or CT imaging:\n\n   \\- Complete ankylosis of at least two regions of the cervical, lumbar, or thoracic spine (i.e., continuous syndesmophyte formation or complete ossification between vertebral bodies).\n4. Presence of other musculoskeletal abnormalities or conditions that may limit exercise performance.\n5. Diagnosis of cancer within the past 5 years\n6. Pregnancy\n7. Regular exercise participation within the past 6 months (defined as exercising for at least 60 minutes per session, three or more times per week).\n8. Major changes in medication for axial spondyloarthritis during the study period, including:\n\n   1. Initiation or discontinuation of biologic agents or targeted therapies.\n   2. Significant changes in the continued use of NSAIDs or sulfasalazine.\n   3. Significant changes in the continued use of systemic glucocorticoids.","59 Years",{"count":114,"type":20},24,[23],"The goal of this clinical trial is to learn if Taekwondo training works to help adults with ankylosing spondylitis and axial spondyloarthritis. It will also learn about the safety of Taekwondo training for these adults.\n\nThe main questions are as follows:\n\n* Will Taekwondo training affect disease activity, functional improvement, and quality of life?\n* Will there be a difference between adults who participate in Taekwondo training and adults who continue with their usual treatment?\n* Is Taekwondo training safe for adults with ankylosing spondylitis and axial spondyloarthritis, and will it be an appropriate exercise for these adults?\n* Is there a possibility to develop a structured Taekwondo-based exercise program for adults with musculoskeletal disorders?\n\nParticipants will:\n\n* Be a part of the Taekwondo training group or the control group for 12 weeks (where the control group will later participate in the same 12 week Taekwondo for comparison)\n* Be assessed within 2 weeks before the start of the training\n* Be assessed within 1 week after completing the training",[118,119],"Ankylosing Spondylitis","Axial Spondyloarthritis",[121,118,119],"Taekwondo","2025-03-20",{"date":124,"type":34},"2025-03-25",{"date":126,"type":20},"2025-03",{"date":128,"type":20},"2025-11",{"name":40,"class":41},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":137,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":140,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":154,"leadSponsor":156,"locationsCount":72},"100583167","home-high-flow-nasal-cannula-vs-noninvasive-ventilation-for-stable-chronic-respiratory-failure-100583167","NCT06872801","Home High-Flow Nasal Cannula vs. Noninvasive Ventilation for Stable Chronic Respiratory Failure","Comparison of the Effects of Home High-Flow Nasal Cannula Therapy and Noninvasive Ventilation in Patients With Stable Chronic Hypercapnic Respiratory Failure","Inclusion Criteria:\n\n* Adult aged 40 years or older\n* Diagnosed with COPD\n* Arterial blood gas test, pCO2 \\> 45 mmHg at stable status\n* A person who can read or write in Korean\n* Written informed consent to participate in this study\n\nExclusion Criteria:\n\n* A person who disagrees with the content of a informed consent\n* Those who have difficulty wearing NIV or HFNC\n* Cognitive impairment or apsychiatric disorder\n* Hypoxic or hypercapnic exacerbation within the previous four weeks","40 Years",{"count":139,"type":20},38,[23],"The goal of this clinical trial is to compare the effects of home high-flow nasal cannula (HFNC) therapy and noninvasive ventilation (NIV) in patients with stable chronic hypercapnic respiratory failure. The main questions it aims to answer are:\n\n* Does HFNC or NIV reduce blood carbon dioxide levels more effectively?\n* How well do patients tolerate and adhere to each therapy?\n* Are there differences in oxygen saturation, respiratory rate, and quality of life between the two treatments?\n\nParticipants Will:\n\n* Use either HFNC (myAirvo2®) or NIV (Trilogy Evo®) every night for at least 4 hours over a 6-week period.\n* Visit the hospital for checkups and arterial blood gas tests at the end of each 6-week period.\n* Switch to the alternate device after six weeks as part of the crossover study design.\n* Have their device usage recorded and analyzed.",[143],"Stable Chronic Hypercapnic Respiratory Failure",[145,146,147,148,149],"Chronic Hypercapnic Respiratory Failure","Noninvasive Ventilation","High-Flow Nasal Cannula","Randomized Controlled Trial","Crossover Design","2025-03-10",{"date":152,"type":34},"2025-03-12",{"date":126,"type":20},{"date":155,"type":20},"2026-06",{"name":40,"class":41},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":169,"studyType":84,"phases":4,"briefSummary":170,"conditions":171,"keywords":174,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":4},"100567991","pharmacogenomics-of-mood-disorder-in-chronic-kidney-disease-patients-100567991","NCT06675396","Pharmacogenomics of Mood Disorder in Chronic Kidney Disease Patients","Cohort Study on the Psychiatric Outcomes and Genetic Associations in Patients With Chronic Kidney Disease","CKD","Inclusion Criteria:\n\n* CKD patients aged 18 to 90 years\n\nExclusion Criteria:\n\n* no CKD patients, aged below 18 or above 90 years","18 Years","90 Years",{"count":168,"type":20},300,"10 Years","By using genetic information we could predict the prevalence of mood disorder and response to treatment.",[172,173],"Chronic Kidney Disease(CKD)","Depression",[163,175],"Mood disorder","2024-11-04",{"date":178,"type":34},"2024-11-05",{"date":180,"type":20},"2024-12-01",{"date":182,"type":20},"2028-12-31",{"name":40,"class":41},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":165,"maxAge":4,"enrollmentInfo":191,"targetDuration":193,"studyType":84,"phases":4,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":207,"locationsCount":72},"100396094","prognostic-value-of-short-term-follow-up-biomarkers-after-discharge-in-hospitalized-patients-with-acute-heart-failure-100396094","NCT04437628","Prognostic Value Of Short-Term Follow-up Biomarkers After Discharge In hOspitalized Patients With Acute Heart Failure","POSTBIO-HF","Inclusion Criteria: the diagnosis of Heart failure requires the following\n\n1. heart failure with reduced ejection fraction ( A 'reduced' ejection fraction (EF) defined as EF \\\u003C40%): the presence of symptoms and\u002For signs of HF\n2. heart failure with preserved ejection fraction ( A 'preserved' EF defined as EF≥ 40%) requires the all of the followings: a) the presence of symptoms and\u002For signs of HF b) elevated levels of natriuretic peptides (defined as B-type natriuretic peptide (BNP) \\>100pg\u002Fml and\u002For N terminal B-type natriuretic peptide (NT-proBNP) \\>300pg\u002Fml) c) any structural heart disease (left atrial volume index ≥ 34 mL\u002Fm2, left atrial dimension ≥ 50 mm, posterior or septal wall thickness ≥ 11mm)\n\nExclusion Criteria:\n\n* any severe condition limiting life less than 3 months\n* the patient is not ready to contact by telephone at the end of the study",{"count":192,"type":20},1500,"12 Months","Several surrogate biomarkers including natriuretic peptide(NP), and growth differentiation factor-15(GDF-15) and ST2 has prognostic significance in heart failure(HF), and reductions in its value may predict clinical improvement. However, there are limited data regarding the prognostic value of these biomarkers during short-term follow-up after discharge in acute decompensated heart failure. The purpose of this study is to evaluate the prognostic value of short-term follow-up surrogate biomarkers for predicting prognosis of hospitalized patients with acute decompensated heart failure.",[196],"Heart Failure",[198,199,200],"Heart failure","Biomarkers","Prognosis","2024-09-06",{"date":203,"type":34},"2024-09-19",{"date":205,"type":34},"2021-02-01",{"date":38,"type":20},{"name":40,"class":41},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":21,"phases":218,"briefSummary":219,"conditions":220,"keywords":224,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":4},"100557616","digital-based-home-care-service-for-ostomy-patients-100557616","NCT06540430","Digital Based Home Care Service for Ostomy Patients","Digital Based Home Care Service for Ostomy Patients: Randomized Controlled Trials","Inclusion Criteria:\n\n* Patients aged 19 years or older\n* Patients who have a colostomy or ileostomy after surgery for colon cancer\n* Patients who do not have difficulty using a smartphone\n\nExclusion Criteria:\n\n* Patients younger than 19 years\n* Patients aged 80 years or older\n* Patients who do not know how to use a smartphone\n* Patients with cognitive impairments\n* Patients with pre-existing psychiatric disorders\n* Patients who have undergone emergency surgery\n* Patients who already have stoma-related complications","79 Years",{"count":217,"type":20},120,[23],"This study aims to enhance the physical, psychological, and social aspects of stoma care by providing a self-management service via a smartphone application, and to evaluate the impact of this digital-based application on patients' quality of life.",[221,222,223],"Colorectal Neoplasms","Stoma Colostomy","Stoma Ileostomy",[225,226,227],"Stoma","Colorectal neoplasms","Quality of life","2024-08-06",{"date":230,"type":34},"2024-08-09",{"date":232,"type":20},"2024-09-01",{"date":234,"type":20},"2026-02-28",{"name":40,"class":41},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":244,"sex":16,"minAge":165,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":21,"phases":248,"briefSummary":249,"conditions":250,"keywords":253,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":72},"100506460","the-safety-of-nafamostat-mesylate-for-patients-with-high-risk-bleeding-undergoing-hemodialysis-a-pilot-study-100506460","NCT05874674","The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study","The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Diathesis Undergoing Hemodialysis: A Pilot Study","Nafamostat","Inclusion Criteria:\n\n* platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month\n\nExclusion Criteria:\n\n* cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)",true,"99 Years",{"count":247,"type":20},100,[23],"Comparison nafamostat and low molecular weight heparin among dialysis patients",[251,252],"Dialysis; Complications","Bleeding",[254,255,256,257],"dialysis","bleeding","nafamostat","heaprin","2024-07-28",{"date":260,"type":34},"2024-07-30",{"date":262,"type":34},"2023-12-01",{"date":264,"type":20},"2026-12-31",{"name":40,"class":41},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":72},"100400137","carbon-monoxide-intoxication-in-korea-prospective-cohort-care-co-cohort-100400137","NCT04490317","CARbon monoxidE intoxiCatiOn in Korea: Prospective Cohort (CARE CO Cohort)","Inclusion Criteria:\n\n* Acute CO poisoning\n\nExclusion Criteria:\n\n* Declined to enrollment in the study",{"count":192,"type":20},"This prospective cohort study enrolls subjects who experience carbon monoxide (CO) poisoning. The purpose of the study is to evaluate therapeutic effects of various treatments and short and long-term outcomes in CO poisoned patients. In addition, complications of brain and heart susceptible to CO are investigated through various ways and the association between complications and the patient's prognosis is also investigated. All subjects will be regularly monitored by physicians participating in this study.",[275,276,277,278,279,280,281],"Carbon Monoxide Poisoning","Myocardial Injury","Neurologic Deficits","Image, Body","Therapy","Prognostic Factors","Complications","2024-07-22",{"date":284,"type":34},"2024-07-23",{"date":286,"type":34},"2020-07-29",{"date":288,"type":20},"2035-12",{"name":40,"class":41},""]